6 completed, 6 recruiting, 5 terminated, 1 active not recruiting. 7 Phase 2, 5 Not applicable, 4 Phase 1, 2 Phase 3.
Follow Leukemia, Acute Lymphoblastic: new trials by email Literature Review of Leukemia, Acute Lymphoblastic trials Research Report on Leukemia, Acute Lymphoblastic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias Autologous HuCD19 ( Anti-CD19)CAR T cells, Cyclophosphamide, Fludarabine - Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 132 | 2024-09-03 | 2026-10-16 |
| CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma CART-19 - Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | University of Sao Paulo | 81 | 2024-03-21 | 2024-12-09 |
| Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients Ponatinib - Chemotherapy, Leukemia, Acute Lymphoblastic | Phase 2 | Active not recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 32 | 2022-10-05 | 2026-03-06 |
| Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy Digital Health Coaching - Lymphoma, Lymphoma, B-Cell | Not applicable | Completed | Pack Health | 45 | 2022-03-11 | 2024-05-24 |
| Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention Functional tests, Next Generation Sequencing analysis, Microvesicles analysis - Myeloid Leukemia, Acute, Leukemia, Acute Lymphoblastic | Not applicable | Recruiting | Azienda Ospedaliero-Universitaria di Parma | 100 | 2022-03-01 | 2024-10-04 |
| CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL Leukemia, Acute Lymphoblastic, Lymphoblastic Leukemia, Acute, Childhood | Completed | National Cancer Institute (NCI) | 57 | 2021-10-14 | 2026-10-26 | |
| Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) Fludarabine, Bendamustine Hydrochloride, Busulfan - Leukemia, Acute Lymphoblastic, Myeloid Leukemia, Acute | Phase 2 | Completed | St. Petersburg State Pavlov Medical University | 50 | 2021-01-21 | 2024-05-07 |
| A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy - Leukemia, Acute Lymphoblastic | Phase 3 | Recruiting | Mats Heyman | 6430 | 2020-07-13 | 2026-08-12 |
| Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia Eskimo-3 Pure Fish Oil, Rapeseed Oil - Leukemia, Acute Lymphoblastic | Not applicable | Recruiting | Copenhagen University Hospital, Rigshospitalet | 100 | 2019-12-16 | 2019-12-26 |
| A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Observational - Leukemia, Acute Lymphoblastic | Recruiting | Mats Heyman | 500 | 2019-08-29 | 2026-08-13 | |
| Safety of Expanded Haploidentical Natural Killer Cells for Leukemia Expanded Haploidentical Natural Killer cells, IL-2 - Leukemia, Acute Myeloid, Leukemia, Acute Lymphoblastic | Phase 1 | Completed | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | 10 | 2019-01-02 | 2022-03-02 |
| CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL CART 19 - Leukemia, Acute Lymphoblastic | Phase 2 | Terminated | University of Pennsylvania | 1 | 2016-10-01 | 2023-06-22 |
| Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses Acute Lymphobastic Leukemia (ALL) Treatment Options - Leukemia, Acute Lymphoblastic | Not applicable | Terminated | New Mexico Cancer Research Alliance | 21 | 2016-07-28 | 2024-01-11 |
| GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia Allogeneic stem cell transplantation, Fludarabine monophosphate, Busulfan - Leukemia, Acute Lymphoblastic, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | St. Petersburg State Pavlov Medical University | 27 | 2016-06-01 | 2020-11-23 |
| Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) Blinatumomab, Dexamethasone, Vincrisitne - Leukemia, Acute Lymphoblastic | Phase 3 | Completed | Amgen | 111 | 2015-11-10 | 2026-06-26 |
| iCare for Cancer Patients Molecular diagnostic testing - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Not applicable | Terminated | University of Florida | 136 | 2015-06-26 | 2019-12-20 |
| Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT Clofarabine, Cyclophosphamide, Etoposide - Leukemia, Acute Lymphoblastic, Acute Myeloid Leukemia | Phase 2 | Terminated | Medical College of Wisconsin | 6 | 2014-12-08 | 2020-03-09 |
| Vincristine PK and PD in the AYA Population Compared to Younger Children Leukemia, Acute Lymphoblastic, Leukemia | Unknown | Children's Hospital Los Angeles | 30 | 2014-09-01 | 2015-06-22 | |
| Acute Lymphoblastic Leukemia Registry at Asan Medical Center Diagnosed as ALL - Leukemia, Acute Lymphoblastic, Precursor B-Cell Lymphoblastic Leukemia | Terminated | Asan Medical Center | 200 | 2013-01-01 | 2018-07-20 | |
| Erwinase Master Treatment Protocol Erwinia L-asparaginase - Leukemia, Acute Lymphoblastic, Acute Lymphoid Leukemia | No longer available | Phoenix Children's Hospital | 2026-01-23 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (20) · Leukemia, Myeloid, Acute (6) · Leukemia (4) · Leukemia, Biphenotypic, Acute (3) · Lymphoma (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Neoplasms (2) · Hematologic Neoplasms (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1)
Hematologic Diseases (20) · Hemic and Lymphatic Diseases (20) · Leukemia, Lymphoid (20) · Lymphatic Diseases (20) · Neoplasms by Histologic Type (20) · Immune System Diseases (19) · Immunoproliferative Disorders (19) · Lymphoproliferative Disorders (19) · Neoplasms (18) · Leukemia (16) · Leukemia, Myeloid (6) · Blood Protein Disorders (2) · Bone Marrow Diseases (2) · Cardiovascular Diseases (2) · Disease Attributes (2)
Cyclophosphamide (3) · Bendamustine Hydrochloride (2) · Busulfan (2) · asparaginase erwinia chrysanthemi recombinant (2) · blinatumomab (2) · fludarabine (2) · Asparaginase (1) · CTL019 chimeric antigen receptor (1) · Capsules (1) · Clofarabine (1) · Daunorubicin (1) · Dexamethasone (1) · Etoposide (1) · Fish Oils (1) · Ifosfamide (1)
Mats Heyman (2) · National Cancer Institute (NCI) (2) · St. Petersburg State Pavlov Medical University (2) · Amgen (1) · Asan Medical Center (1) · Azienda Ospedaliero-Universitaria di Parma (1) · Belarusian Research Center for Pediatric Oncology, Hematology and Immunology (1) · Children's Hospital Los Angeles (1) · Copenhagen University Hospital, Rigshospitalet (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Medical College of Wisconsin (1) · New Mexico Cancer Research Alliance (1) · Pack Health (1) · Phoenix Children's Hospital (1) · University of Florida (1)
United States (8) · Denmark (4) · Italy (3) · Norway (3) · Russia (3) · Spain (3) · Sweden (3) · Belgium (2) · Brazil (2) · Estonia (2) · Finland (2) · France (2) · Germany (2) · Iceland (2) · Lithuania (2)
Boris V. Afanasyev, Professor (1) · Christopher R. Cogle, MD (1) · Dae-Young Kim, MD, PhD (1) · Diego V Cle, MD, PhD, MBA (1) · James N Kochenderfer, M.D. (1) · Jodi Mayfield, MD (1) · Lakshmi Damerla (1) · Mats Heyman, M.D. PhD (1) · Mats Heyman, MD, PhD (1) · Michael J Burke, MD (1) · Noelle Frey, MD (1) · Olga Aleinikova (1) · Sabina Chiaretti (1) · Sara K Silbert, M.D. (1)
PMID 35501736, PMID 36527513, PMID 39214018, PMID 41262029
2014 (1)